Clinical features and management of primary biliary cirrhosis.
暂无分享,去创建一个
[1] J. Rodés,et al. Epidemiology of primary biliary cirrhosis. , 2008, Liver.
[2] M. Allocca,et al. Primary Biliary Cirrhosis is not an Additional Risk Factor for Bone Loss in Women Receiving Regular Calcium and Vitamin D Supplementation: A Controlled Longitudinal Study , 2008, Journal of clinical gastroenterology.
[3] M. Kaplan,et al. Quality of life and everyday activities in patients with primary biliary cirrhosis , 2007, Hepatology.
[4] M. Vergara,et al. Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community , 2007, European journal of gastroenterology & hepatology.
[5] W. März,et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid , 2007, Hepatology.
[6] David C. Jones,et al. Population prevalence and symptom associations of autonomic dysfunction in primary biliary cirrhosis , 2007, Hepatology.
[7] M. Freeston,et al. The role of psychological factors in the fatigue of primary biliary cirrhosis , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[8] J. Oosting,et al. Ondansetron and pruritus in chronic liver disease: a controlled study. , 2007, Hepato-gastroenterology.
[9] J. Talwalkar,et al. Clinical Epidemiology of Primary Biliary Cirrhosis: Incidence, Prevalence, and Impact of Therapy , 2007, Journal of clinical gastroenterology.
[10] Westgate Road,et al. Autonomic Dysfunction in Primary Biliary Cirrhosis Correlates with Fatigue Severity. , 2007 .
[11] A. Rush,et al. Sertraline as a first‐line treatment for cholestatic pruritus , 2007, Hepatology.
[12] V. Salomaa,et al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland , 2007, Scandinavian journal of gastroenterology.
[13] Westgate Road,et al. Reduced heart rate variability and baroreflex sensitivity in primary biliary cirrhosis , 2006 .
[14] S. Klingenberg,et al. Systematic review and meta‐analysis: D‐Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis – Cochrane Hepato‐Biliary Group , 2006, Alimentary pharmacology & therapeutics.
[15] M. Allocca,et al. Inadequate dietary intake but not renal tubular acidosis is associated with bone demineralization in primary biliary cirrhosis , 2006, Alimentary pharmacology & therapeutics.
[16] J. Talwalkar,et al. Fluoxetine for the Treatment of Fatigue in Primary Biliary Cirrhosis: A Randomized, Double-Blind Controlled Trial , 2006, Digestive Diseases and Sciences.
[17] J. Newton,et al. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence , 2006, Hepatology.
[18] J. Węsierska‐Gądek,et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis , 2006, Hepatology.
[19] D. Caruso,et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis , 2006, Gut.
[20] J. Rodés,et al. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. , 2006, Gastroenterology.
[21] A. Branch,et al. Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites , 2006, Hepatology.
[22] J. Talwalkar,et al. Polluting the pathogenesis of primary biliary cirrhosis , 2006, Hepatology.
[23] N. Bhala,et al. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort , 2005, Gut.
[24] A. West,et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis , 2005, Hepatology.
[25] M. Kaplan,et al. Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview‐based study of 1032 patients , 2005, Hepatology.
[26] A. Burroughs,et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis , 2005, Gut.
[27] M. Kaplan,et al. The natural history of PBC: has it changed? , 2005, Seminars in liver disease.
[28] S. Sahlin,et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. , 2005, Gastroenterology.
[29] G. Tomlinson,et al. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue , 2005, Hepatology.
[30] M. Färkkilä,et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial , 2005, Hepatology.
[31] J. Rodés,et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. , 2005, Journal of hepatology.
[32] Roger Williams,et al. A controlled trial of ondansetron in the pruritus of cholestasis , 2005, Alimentary pharmacology & therapeutics.
[33] R. Chapman,et al. Fatigue is not a specific symptom in patients with primary biliary cirrhosis , 2005, European journal of gastroenterology & hepatology.
[34] F. Carrat,et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. , 2005, Gastroenterology.
[35] P. Angus,et al. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. , 2004, Gastroenterology.
[36] Y. Chrétien,et al. Quality of life in patients with primary biliary cirrhosis , 2004, Hepatology.
[37] R. Gish,et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. , 2004, Gastroenterology.
[38] R. Hultcrantz,et al. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis , 2004, Journal of internal medicine.
[39] A. Chetwynd,et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort , 2004, Gut.
[40] P. Milkiewicz,et al. Fatigue in chronic cholestasis , 2004, Gut.
[41] J. Hajnal,et al. Fatigue and primary biliary cirrhosis: association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels , 2004, Gut.
[42] R. Williams,et al. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1‐year controlled trial , 2004, Alimentary pharmacology & therapeutics.
[43] C. Selmi,et al. Frequency of monosomy X in women with primary biliary cirrhosis , 2004, The Lancet.
[44] J. Rodés,et al. Natural history of primary biliary cirrhosis. , 2003, Clinics in liver disease.
[45] J. Rodés,et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis , 2003, American Journal of Gastroenterology.
[46] W. Leslie,et al. AGA technical review on osteoporosis in hepatic disorders. , 2003, Gastroenterology.
[47] J. Neuberger. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. , 2003, Journal of hepatology.
[48] J. Talwalkar,et al. Primary biliary cirrhosis , 2003, The Lancet.
[49] J. Talwalkar,et al. Natural history of pruritus in primary biliary cirrhosis. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[50] D. Jones,et al. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo‐controlled, cross‐over trial , 2003, Alimentary pharmacology & therapeutics.
[51] H. Mallmin,et al. Longitudinal bone loss in postmenopausal women with primary biliary cirrhosis and well‐preserved liver function , 2002, Journal of internal medicine.
[52] A. Chetwynd,et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. , 2002, Gastroenterology.
[53] B. McMahon,et al. Prevalence of autoimmune liver disease in Alaska natives , 2002, American Journal of Gastroenterology.
[54] U. Beuers,et al. Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited , 2002, Hepatology.
[55] P. Invernizzi,et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis , 2002, Gut.
[56] E. Schiff,et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease , 2002, American Journal of Gastroenterology.
[57] S. Hadziyannis,et al. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial , 2002, American Journal of Gastroenterology.
[58] David E. J. Jones,et al. The true impact of fatigue in primary biliary cirrhosis: a population study. , 2002, Gastroenterology.
[59] V. Armstrong,et al. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. , 2002, Journal of hepatology.
[60] David C. Jones,et al. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis , 2002, Gut.
[61] Peter Diggle,et al. The geographical distribution of primary biliary cirrhosis in a well‐defined cohort , 2001, Hepatology.
[62] E. Dickson,et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. , 2001, Journal of hepatology.
[63] M. Allocca,et al. Ten‐year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double‐blind, placebo‐controlled trial on symptomatic patients , 2001, Alimentary pharmacology & therapeutics.
[64] J. Newton,et al. Osteoporosis in primary biliary cirrhosis revisited , 2001, Gut.
[65] M. Podda,et al. Hyperlipidemia in chronic cholestatic liver disease , 2001, Current treatment options in gastroenterology.
[66] M. Petroni,et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. , 2001, Journal of lipid research.
[67] E. Gold,et al. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States , 2001, Hepatology.
[68] E. Dickson,et al. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. , 2000, Journal of hepatology.
[69] T. Therneau,et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. , 2000, Gastroenterology.
[70] C. Fischbacher,et al. An exploratory population‐based case‐control study of primary biliary cirrhosis , 2000, Hepatology.
[71] J. Rodés,et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial , 2000 .
[72] E. Heathcote. Management of primary biliary cirrhosis , 2000 .
[73] A. Tran,et al. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis , 2000, American Journal of Gastroenterology.
[74] E. Dickson,et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid , 2000, Hepatology.
[75] M. Kaplan,et al. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. , 1999, Gastroenterology.
[76] H. Ackermann,et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. , 1999, Gastroenterology.
[77] A. Burroughs,et al. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis , 1999, The Lancet.
[78] R. Coppel,et al. Familial primary biliary cirrhosis in Hiroshima. , 1999, Journal of autoimmunity.
[79] D. Howel,et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? , 1999, Hepatology.
[80] D. Gleeson,et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. , 1999, Gastroenterology.
[81] H. Mallmin,et al. Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. , 1999, Journal of hepatology.
[82] N. Bergasa,et al. The pruritus of cholestasis , 1999, Hepatology.
[83] David C. Jones,et al. Familial primary biliary cirrhosis reassessed: a geographically-based population study. , 1999, Journal of hepatology.
[84] M. Schemper,et al. Treatment of pruritus in chronic liver disease with the 5‐hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo‐controlled, double‐blind cross‐over trial , 1998, European journal of gastroenterology & hepatology.
[85] O. Chazouilleres,et al. Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: Clinical features and response to therapy , 1998, Hepatology.
[86] T. Therneau,et al. Incidence of cancer in primary biliary cirrhosis: The mayo experience , 1998, Hepatology.
[87] D. Alling,et al. Open‐label trial of oral nalmefene therapy for the pruritus of cholestasis , 1998 .
[88] D. R. Parker,et al. The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences , 1998, Gut.
[89] T. Therneau,et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. , 1997, Mayo Clinic proceedings.
[90] W. Hop,et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. , 1997, Gastroenterology.
[91] E. Dickson,et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. , 1997, Gastroenterology.
[92] R. Bhopal,et al. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. , 1997, International journal of epidemiology.
[93] J. Rodés,et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. , 1997, Gastroenterology.
[94] V. Balakrishnan,et al. Primary biliary cirrhosis with pruritus in India. , 1997, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.
[95] M. Cumsille,et al. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. , 1997, Journal of hepatology.
[96] M. Kaplan,et al. Sustained Biochemical and Histologic Remission of Primary Biliary Cirrhosis in Response to Medical Treatment , 1997, Annals of Internal Medicine.
[97] A. Larghi,et al. Comparison of the clinical features and clinical course of antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis , 1997, Hepatology.
[98] B. Combes,et al. Ursodeoxycholic Acid in Primary Biliary Cirrhosis , 1997, Seminars in liver disease.
[99] F. Perlík,et al. [Ursodeoxycholic acid in the treatment of primary biliary cirrhosis]. , 1997, Casopis lekaru ceskych.
[100] K. Einarsson,et al. Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. , 1997, Scandinavian journal of gastroenterology.
[101] W. Hop,et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. , 1997, Journal of hepatology.
[102] E. Zafrani,et al. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis , 1996 .
[103] G. Minuk,et al. Clinical hepatology: Profile of an urban, hospital‐based practic , 1996, Hepatology.
[104] G. V. van Dam,et al. Primary biliary cirrhosis (PBC) in an European country--a description of death rates in The Netherlands (1979-1992). , 1996, Hepato-gastroenterology.
[105] J. Neuberger,et al. End-stage primary biliary cirrhosis in a first generation migrant south Asian population. , 1996, European journal of gastroenterology & hepatology.
[106] S. Matern,et al. Stimulation of bile acid 6α-hydroxylation by rifampin , 1996 .
[107] T. Therneau,et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. , 1996, Gastroenterology.
[108] E. Dickson,et al. Time course of histological progression in primary biliary cirrhosis , 1996, Hepatology.
[109] D. Alling,et al. Effects of Naloxone Infusions in Patients with the Pruritus of Cholestasis: A Double-Blind, Randomized, Controlled Trial , 1995, Annals of Internal Medicine.
[110] P. Angus,et al. Low prevalence of primary biliary cirrhosis in Victoria, Australia. Melbourne Liver Group. , 1995, Gut.
[111] M. Färkkilä,et al. Serum cholestanol, cholesterol precursors, and plant sterols during placebo‐controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine , 1995, Hepatology.
[112] N. Bergasa,et al. The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. , 1995, Gastroenterology.
[113] M. Färkkilä,et al. Other clinical studySerum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine☆ , 1995 .
[114] G. Ramadori,et al. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron , 1995, Pain.
[115] R. Uibo,et al. Primary biliary cirrhosis in Estonia. With special reference to incidence, prevalence, clinical features, and outcome. , 1995, Scandinavian journal of gastroenterology.
[116] E. Dickson,et al. Bone disease in primary biliary cirrhosis: Does ursodeoxycholic acid make a difference? , 1995, Hepatology.
[117] J. Boyer,et al. Primary Biliary Cirrhosis: Survival of a Large Cohort of Symptomatic and Asymptomatic Patients Followed for 24 Years , 1995 .
[118] P. Battezzati,et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis , 1994, Hepatology.
[119] M. Kaplan,et al. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. , 1994, Gastroenterology.
[120] P. Grambsch,et al. Primary biliary cirrhosis: Prediction of short‐term survival based on repeated patient visits , 1994, Hepatology.
[121] W. Scheithauer,et al. Ondansetron for pruritus due to cholestasis. , 1994, The New England journal of medicine.
[122] B. Balkau,et al. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. , 1994, The New England journal of medicine.
[123] U. Steinbrecher,et al. The canadian multicenter double‐blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis , 1994, Hepatology.
[124] A. West,et al. A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis , 1993, Hepatology.
[125] G. Ramadori,et al. Improvement of cholestatic pruritus by ondansetron , 1993, The Lancet.
[126] Y. Chrétien,et al. Cholesterol‐lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis , 1993, Hepatology.
[127] N Tygstrup,et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. , 1993, Gastroenterology.
[128] Y. Ilan,et al. Primary biliary cirrhosis in Israel. , 1992, Israel journal of medical sciences.
[129] N. Bergasa,et al. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis. , 1992, Gastroenterology.
[130] D. A. Thomas,et al. Effects of central administration of opioids on facial scratching in monkeys , 1992, Brain Research.
[131] C. Record,et al. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. , 1992, Journal of hepatology.
[132] A. Parés,et al. Effects of long-term rifampicin administration in primary biliary cirrhosis , 1992 .
[133] F. Schaffner,et al. Long‐term follow‐up of patients with primary biliary cirrhosis on colchicine therapy , 1991, Hepatology.
[134] P. Battezzati,et al. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration , 1991, Hepatology.
[135] M. Kaplan,et al. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. , 1991, Gastroenterology.
[136] E. Dickson,et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis , 1991, Hepatology.
[137] B. Balkau,et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. , 1991, The New England journal of medicine.
[138] T. Almdal,et al. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: Analysis of hospitalization registry data , 1991, Hepatology.
[139] S. Giannini,et al. Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment. , 1991, Journal of hepatology.
[140] F. Villamil,et al. Treatment of pruritus of primary biliary cirrhosis with rifampin , 1991, Digestive Diseases and Sciences.
[141] H. Pols,et al. Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids. , 1990, Gastroenterology.
[142] J. Rankin,et al. The demography of primary biliary cirrhosis in ontario, canada , 1990, Hepatology.
[143] N. Bergasa,et al. Hypothesis the pruritus of cholestasis: From bile acids to opiate agonists , 1990 .
[144] O. James,et al. The epidemiology of primary biliary cirrhosis in north-east England: an increasingly common disease? , 1990, The Quarterly journal of medicine.
[145] P. Uddenfeldt,et al. Epidemiology of primary biliary cirrhosis in a defined rural population in the northern part of Sweden , 1990, Hepatology.
[146] E. Schrumpf,et al. Factors of prognostic importance in primary biliary cirrhosis. , 1990, Scandinavian journal of gastroenterology.
[147] K. Kashima,et al. Unusual trihydroxy bile acids in the urine of patients treated with chenodeoxycholate, ursodeoxycholate or rifampicin and those with cirrhosis , 1990, Hepatology.
[148] P. Grambsch,et al. Extramural cross‐validation of the mayo primary biliary cirrhosis survival model establishes its generalizability , 1989, Hepatology.
[149] C. Record,et al. A pilot, double‐blind, controlled 1‐year trial of prednisolone treatment in primary biliary cirrhosis: Hepatic improvement but greater bone loss , 1989, Hepatology.
[150] P. Boyle,et al. Risk factors and prognosis in primary biliary cirrhosis. , 1989, The American journal of gastroenterology.
[151] P. Grambsch,et al. Prognosis in primary biliary cirrhosis: Model for decision making , 1989, Hepatology.
[152] A. Parés,et al. COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS , 1989, The Lancet.
[153] M. Losowsky,et al. Opioid peptides and primary biliary cirrhosis. , 1988, BMJ.
[154] F. Schaffner,et al. Evaluation of colchicine therapy in primary biliary cirrhosis. , 1988, Gastroenterology.
[155] S. Carruthers,et al. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. , 1988, Gastroenterology.
[156] H. Popper,et al. URSODEOXYCHOLIC ACID FOR PRIMARY BILIARY CIRRHOSIS , 1987, The Lancet.
[157] Ghent Cn. Pruritus of cholestasis is related to effects of bile salts on the liver, not the skin. , 1987 .
[158] M. Kaplan,et al. A prospective trial of colchicine for primary biliary cirrhosis. , 1986, The New England journal of medicine.
[159] J. Hoofnagle,et al. Randomized trial of chlorambucil for primary biliary cirrhosis. , 1986, Gastroenterology.
[160] K. Mann,et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. , 1985, Annals of internal medicine.
[161] J. Roll. A new treatment for primary biliary cirrhosis? , 1985, Gastroenterology.
[162] D. Altman,et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. , 1985, Gastroenterology.
[163] E. Dickson,et al. Pathogenesis of steatorrhea in primary biliary cirrhosis , 1985, Hepatology.
[164] G. Järnerot,et al. Incidence and prevalence of primary biliary cirrhosis in a defined population in Sweden. , 1985, Scandinavian journal of gastroenterology.
[165] S. Lindgren,et al. The prevalence and clinical spectrum of primary biliary cirrhosis in a defined population. , 1984, Scandinavian journal of gastroenterology.
[166] I. Rosenberg,et al. Intestinal Calcium Absorption and Vitamin D Status in Chronic Cholestatic Liver Disease , 1984, Hepatology.
[167] O. James,et al. Primary biliary cirrhosis: geographical clustering and symptomatic onset seasonality. , 1983, Gut.
[168] J. Boyer,et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. , 1983, The New England journal of medicine.
[169] H. Fischer,et al. Spinal opiate analgesia and facial pruritus: a neural theory , 1982, Postgraduate medical journal.
[170] J. Summerfield,et al. Bile acid profiles of human serum and skin interstitial fluid and their relationship to pruritus studied by gas chromatography-mass spectrometry. , 1982, Clinical science.
[171] Jjm,et al. Intraspinal opiates and itching: a new reflex? , 1982, British medical journal.
[172] A. Macklon,et al. PRIMARY BILIARY CIRRHOSIS—A REVISED CLINICAL SPECTRUM , 1981, The Lancet.
[173] R. Holzbach,et al. Pruritus in cholestasis: no direct causative role for bile acid retention. , 1981, The American journal of medicine.
[174] D. Triger. Primary biliary cirrhosis: an epidemiological study. , 1980, British medical journal.
[175] F. Schaffner,et al. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. , 1979, Gut.
[176] J. Bloomer,et al. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus. , 1977, Gastroenterology.
[177] R. P. Thompson,et al. INTESTINAL ABSORPTION OF 25-HYDROXYVITAMIN D AND OSTEOMALACIA IN PRIMARY BILIARY CIRRHOSIS , 1977, The Lancet.
[178] S. Sherlock,et al. A prospective controlled trial of azathioprine in primary biliary cirrhosis. , 1976, Gastroenterology.
[179] J. Burton,et al. Pruritic Effect of Bile Salts , 1974, British medical journal.
[180] S. Sherlock,et al. The epidemiology of primary biliary cirrhosis: A survey of mortality in England and Wales , 1974, Gut.
[181] D. Varadi. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. , 1974, Archives of dermatology.
[182] S. Sherlock,et al. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. , 1973, The New England journal of medicine.
[183] J. Herndon. Pathophysiology of pruritus associated with elevated bile acid levels in serum. , 1972, Archives of internal medicine.
[184] D. V. Datta,et al. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. , 1966, Gastroenterology.
[185] J. B. Carey,et al. Relief of the pruritus of jaundice with a bile-acid sequestering resin. , 1961, JAMA.
[186] B. Fell. Osteoporosis in primary biliary cirrhosis:A randomized trial of the efficacy and feasibility of estrogen/progestin , 2006 .
[187] K. Lindor,et al. Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo‐controlled trial , 2005, Hepatology.
[188] W. Kirch,et al. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis , 2004, European Journal of Clinical Pharmacology.
[189] J. Neuberger,et al. Liver transplantation for primary biliary cirrhosis. , 2003, Autoimmunity reviews.
[190] T. Therneau,et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. , 2000, Gastroenterology.
[191] E. Heathcote. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. , 2000, Hepatology.
[192] K. O'rourke,et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis , 1999, American Journal of Gastroenterology.
[193] K. Boberg,et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. , 1998, Scandinavian journal of gastroenterology.
[194] S. Matern,et al. Stimulation of bile acid 6 alpha-hydroxylation by rifampin. , 1996, Journal of hepatology.
[195] E. Dickson,et al. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. , 1994, The American journal of gastroenterology.
[196] F. Schaffner,et al. Familial primary biliary cirrhosis. , 1994, Journal of hepatology.
[197] A. Parés,et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. , 1992, Gastroenterology.
[198] S J Pocock,et al. Prediction of short-term survival with an application in primary biliary cirrhosis. , 1992, Statistics in medicine.
[199] I. Mackay,et al. Primary biliary cirrhosis: paradigm or paradox for autoimmunity. , 1991, Gastroenterology.
[200] J. Villeneuve,et al. Descriptive Epidemiology of Primary Biliary Cirrhosis in the Province of Quebec , 1991 .
[201] N. Mcintyre,et al. Poor prognostication for survival of individual PBC patients with Cox models , 1990 .
[202] A. Nyberg,et al. Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease. , 1989, Scandinavian journal of gastroenterology.
[203] L. Hunt,et al. A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. , 1987, Journal of hepatology.
[204] M. Kaplan,et al. Primary biliary cirrhosis. , 1987, The New England journal of medicine.
[205] D. Alvaro,et al. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids. , 1986, Medical hypotheses.
[206] J. Sjövall,et al. Mass spectrometry of bile acids. , 1985, Methods in enzymology.
[207] P. Scheuer. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. , 1983, Postgraduate medical journal.
[208] Scheuer Pj. Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. , 1983 .
[209] J. Sjövall,et al. Bile Acids on the Skin of Patients with Pruritic Hepatobiliary Disease , 1967, Nature.